As the US approaches the tenth anniversary of its first biosimilar approval and launch, things could be going better for the market. That was the overall impression provided at the Association for Accessible Medicines’ Access! 2025 meeting in Amelia Island, Florida, at the start of February, especially during a session that highlighted the lack of biosimilar competition for most of the biologics that are facing an upcoming loss of exclusivity over the next decade.
AAM Stares Into The Biosimilar Void
Report Offers ‘Sobering Wake-Up Call’ For Stakeholders
Discussing a new report highlighting the lack of US biosimilar competition on the cards for the majority of biologics losing exclusivity in the next ten years, the AAM’s Access! 2025 conference heard that the “sobering” findings should act as a “wake-up call for stakeholders.”
